Login to Your Account

United's court victory protects Remodulin

By Michael Fitzhugh
Staff Writer

Tuesday, September 2, 2014
United Therapeutics Corp. has prevailed in a legal effort to slow Sandoz Inc.'s plans to launch a generic version of the pulmonary arterial hypertension (PAH) therapy Remodulin (treprostinil), a drug that accounted for 44 percent of its revenue last year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription